Award Synopsis SRI.pdf
PDF 91 KB Posted
- Solicitation number
- 75N93019R00023
About this file
This award synopsis announces a contract awarded to SRI International for preclinical and translational vaccine development for HIV and other candidate agents. Key details include: SRI International was awarded contract number 75N93022D00007 for a maximum amount of $364,553,934 under an indefinite-delivery/indefinite-quantity contract with a period of performance from December 1, 2021 through November 30, 2028. The contract was awarded by the National Institute of Allergy and Infectious Diseases to support preclinical and translational vaccine development for HIV and other candidate agents under solicitation number 75N93019R00023. Work will be performed by SRI International in Menlo Park, California.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
AWARD SYNOPSIS
Type: Award
Date of Award: December 1, 2021
Period of Performance (including all options): December 1, 2021 through November 30, 2028
Title: "PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR
HIV AND OTHER CANDIDATE AGENTS”
(RFP) No.: 75N93019R00023
NAICS: 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Contract Number: 75N93022D00007
Total Estimated Cost (Including all Options): $364,553,934 maximum amount (IDIQ)
Place of Performance/Awardee:
SRI International 333 Ravenswood Avenue Menlo Park, CA 94025
DUNS: 009232752
Primary Point of Contact at NIAID: Kishan Patel Contracting Officer patelki@niaid.nih.gov mailto:patelki@niaid.nih.gov
File details come from the government source that posted it. Updated .